Literature DB >> 24114661

Pyrroloquinoline quinone inhibits oxygen/glucose deprivation-induced apoptosis by activating the PI3K/AKT pathway in cardiomyocytes.

Feng Xu1, Haixia Yu, Jinyao Liu, Lu Cheng.   

Abstract

The purposes of this study were to examine the protective effect of pyrroloquinoline quinone (PQQ) on oxygen/glucose deprivation (OGD)-induced injury to H9C2 rat cardiomyocytes and to investigate the mechanism. Using H9C2 cells cultured in vitro, we examined changes in cell viability with an MTT assay at 12, 24, and 48 h after injury induced by OGD. Various concentrations of PQQ (1, 10, and 100 μM) were added, and the effect of PQQ on cell viability after OGD was assessed using the MTT assay. Thus, the optimal concentration of PQQ for the protection of cardiomyocytes against oxygen and glucose deprivation injury was determined. We also used flow cytometry analysis to examine the effect of PQQ on H9C2 cells with OGD-induced injury. The molecular probe 2',7'-dichlorofluorescin diacetate was used to label the H9C2 cells, and flow cytometry was used to detect the effect of PQQ on reactive oxygen species (ROS) content. After labeling the H9C2 cells using a mitochondrial green fluorescent probe (Mito-Tracker Green), we measured the change in the mitochondrial content of PQQ-treated H9C2 cells. Western blotting was used to examine the effect of PQQ on the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in the H9C2 cells. The results of the MTT assay showed that 48 h of OGD significantly injured the H9C2 cells (p < 0.01) and that treatment with 100 μM PQQ effectively decreased the level of OGD-induced injury (p < 0.01). The results of the flow cytometry analysis showed that PQQ significantly reduced apoptosis in H9C2 cells subjected to OGD (p < 0.05). In addition, OGD significantly increased the ROS level in H9C2 cells (p < 0.01), and PQQ significantly inhibited this increase (p < 0.05). The results of the Mito-Tracker Green staining suggested that PQQ effectively inhibited the decrease in mitochondrial content caused by OGD (p < 0.05). Western blot analysis showed that PQQ partially reversed the decrease in Akt phosphorylation that was caused by OGD (p < 0.05). PQQ treatment dose-dependently protects H9C2 cells from OGD-induced injury by reducing apoptosis, decreasing intracellular ROS levels, and rescuing the OGD-induced decrease in mitochondrial content. The protective effect of PQQ may be related to its effects on the PI3K/Akt pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24114661     DOI: 10.1007/s11010-013-1849-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

1.  Middle age aggravates myocardial ischemia through surprising upholding of complex II activity, oxidative stress, and reduced coronary perfusion.

Authors:  Evangelia Mourmoura; Marie Leguen; Hervé Dubouchaud; Karine Couturier; Damien Vitiello; Jean-Luc Lafond; Melanie Richardson; Xavier Leverve; Luc Demaison
Journal:  Age (Dordr)       Date:  2010-09-29

Review 2.  The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

Authors:  Antonella De Luca; Monica R Maiello; Amelia D'Alessio; Maria Pergameno; Nicola Normanno
Journal:  Expert Opin Ther Targets       Date:  2012-03-23       Impact factor: 6.902

Review 3.  Hyperoxygenated solutions in clinical practice: preventing or reducing hypoxic injury.

Authors:  H Xu; Y Li; W Gao; H Zhang; L-X Xu
Journal:  J Int Med Res       Date:  2011       Impact factor: 1.671

4.  bFGF inhibits ER stress induced by ischemic oxidative injury via activation of the PI3K/Akt and ERK1/2 pathways.

Authors:  Zhouguang Wang; Hongyu Zhang; Xinlong Xu; Hongxue Shi; Xichong Yu; Xiaojie Wang; Yongbo Yan; Xiaobing Fu; Houwen Hu; Xiaokun Li; Jian Xiao
Journal:  Toxicol Lett       Date:  2012-05-15       Impact factor: 4.372

5.  Combined resistance and aerobic training is more effective than aerobic training alone in people with coronary artery disease.

Authors:  Bill Brennan
Journal:  J Physiother       Date:  2012       Impact factor: 7.000

Review 6.  Characteristics and advantages of traditional Chinese medicine in the treatment of acute myocardial infarction.

Authors:  Hong-Xu Liu; Shuo-Ren Wang; Yan Lei; Ju-Ju Shang
Journal:  J Tradit Chin Med       Date:  2011-12       Impact factor: 0.848

Review 7.  Coronary CT angiography with prospective ECG-triggering: an effective alternative to invasive coronary angiography.

Authors:  Zhonghua Sun
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

Review 8.  Glucose oxidation and PQQ-dependent dehydrogenases in Gluconobacter oxydans.

Authors:  Tina Hölscher; Ute Schleyer; Marcel Merfort; Stephanie Bringer-Meyer; Helmut Görisch; Hermann Sahm
Journal:  J Mol Microbiol Biotechnol       Date:  2008-10-29

Review 9.  Potential physiological importance of pyrroloquinoline quinone.

Authors:  Robert Rucker; Winyoo Chowanadisai; Masahiko Nakano
Journal:  Altern Med Rev       Date:  2009-09

Review 10.  The PQQ-alcohol dehydrogenase of Gluconacetobacter diazotrophicus.

Authors:  Saúl Gómez-Manzo; Martha Contreras-Zentella; Alejandra González-Valdez; Martha Sosa-Torres; Roberto Arreguín-Espinoza; Edgardo Escamilla-Marván
Journal:  Int J Food Microbiol       Date:  2007-12-08       Impact factor: 5.277

View more
  12 in total

1.  Isoflurane reduces oxygen-glucose deprivation-induced oxidative, inflammatory, and apoptotic responses in H9c2 cardiomyocytes.

Authors:  Jun Liu; Shuangmei Yang; Xiaoran Zhang; Guoze Liu; Xiuqin Yue
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Pyrroloquinoline quinone protects nucleus pulposus cells from hydrogen peroxide-induced apoptosis by inhibiting the mitochondria-mediated pathway.

Authors:  Lianjun Yang; Zijie Rong; Mingjun Zeng; Yanlin Cao; Xumeng Gong; Lijun Lin; Yong Chen; Wei Cao; Lixin Zhu; Weiren Dong
Journal:  Eur Spine J       Date:  2014-10-28       Impact factor: 3.134

3.  Pyrroloquinoline Quinine and LY294002 Changed Cell Cycle and Apoptosis by Regulating PI3K-AKT-GSK3β Pathway in SH-SY5Y Cells.

Authors:  Hongyun Ji; Junxiang Ma; Li Chen; Tian Chen; Shixuan Zhang; Jiaxin Jia; Xin Yang; Caixia Guo; Zhongxin Xiao; Piye Niu
Journal:  Neurotox Res       Date:  2020-05-08       Impact factor: 3.911

4.  Pyrroloquinoline quinone can prevent chronic heart failure by regulating mitochondrial function.

Authors:  Xuan Xu; Chu Chen; Wen-Jiang Lu; Yi-Ling Su; Jia-Yu Shi; Yu-Chen Liu; Li Wang; Chen-Xi Xiao; Xiang Wu; Qi Lu
Journal:  Cardiovasc Diagn Ther       Date:  2020-06

5.  Silencing circular RNA circ_0010729 protects human cardiomyocytes from oxygen-glucose deprivation-induced injury by up-regulating microRNA-145-5p.

Authors:  Qifeng Jin; Yuanyuan Chen
Journal:  Mol Cell Biochem       Date:  2019-09-03       Impact factor: 3.396

6.  Pyrroloquinoline quinone attenuates isoproterenol hydrochloride‑induced cardiac hypertrophy in AC16 cells by inhibiting the NF‑κB signaling pathway.

Authors:  Junru Wen; Junwei Shen; Yajie Zhou; Xianhui Zhao; Zhensheng Dai; Yueling Jin
Journal:  Int J Mol Med       Date:  2020-01-10       Impact factor: 4.101

7.  Pyrroloquinoline Quinone Modifies Lipid Profile, but Not Insulin Sensitivity, of Palmitic Acid-Treated L6 Myotubes.

Authors:  Elżbieta Supruniuk; Agnieszka Mikłosz; Adrian Chabowski
Journal:  Int J Mol Sci       Date:  2020-11-08       Impact factor: 5.923

8.  Inhibit inflammation and apoptosis of pyrroloquinoline on spinal cord injury in rat.

Authors:  Qiao Zhou; Hui Jin; Naiqi Shi; Shumei Gao; Xiaoyu Wang; Shunxing Zhu; Meijuan Yan
Journal:  Ann Transl Med       Date:  2021-09

Review 9.  Chronic over-nutrition and dysregulation of GSK3 in diseases.

Authors:  Xunxian Liu; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2016-08-04       Impact factor: 4.169

10.  Pyrroloquinoline quinone regulates the redox status in vitro and in vivo of weaned pigs via the Nrf2/HO-1 pathway.

Authors:  Caiyun Huang; Zijuan Fan; Dandan Han; Lee J Johnston; Xi Ma; Fenglai Wang
Journal:  J Anim Sci Biotechnol       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.